MADISON HEIGHTS, Mich., Sept. 28, 2025 /PRNewswire/ — Mopec, a leader in pathology and anatomy innovation, is proud to announce the next chapter in its collaboration with Lumea, a pioneer in digital pathology technology. Building on the companies’ existing partnership, Mopec will integrate Lumea’s patented tissue-handling technology directly into the Mopec Maestro® Encore Grossing Station, further advancing diagnostic accuracy and workflow efficiency for pathology professionals.
Beginning October 1, 2025, the Lumea device integration will be available as an optional feature on the Maestro Encore. On January 1, 2026, it will become a standard feature, ensuring pathology labs worldwide benefit from this streamlined solution that bridges specimen grossing with digital pathology workflows.
“This next phase of our partnership with Lumea reinforces Mopec’s commitment to driving innovation that directly benefits patients and laboratory professionals,” said Francis X. Dirksmeier, CEO at Mopec Group. “By integrating Lumea’s technology into the Maestro Encore, we are delivering a comprehensive solution that empowers laboratories to achieve greater accuracy, efficiency, and consistency in diagnosis.”
Mopec Group is also proud to be participating at the Lumea Summit this month, serving on the panel “Climbing Together: How the Diagnostic Ecosystem Reaches the Summit.” Their participation underscores Mopec’s commitment to collaboration and innovation in pathology, as the industry moves toward more connected and technology-driven diagnostic practices.
In addition to device integration, Mopec is excited to announce its role as the exclusive supplier of Lumea consumable products, which will be available for purchase through Mopec’s website and distributor channels. These pre-analytical tissue-handling devices are designed to preserve tissue quality, increase tissue yield, and ultimately ensure the most accurate diagnosis for patients.
- BxBoard®: An advanced tissue collection and transport device that replaces formaldehyde bottles, simplifying workflows for surgery centers and laboratory staff while improving tissue quality. Available in multiple configurations to meet the unique needs of each lab.
- BxChip®: A biomimetic organic polymer chip that securely holds and preserves up to six needle-core biopsies in consistent orientation. The chip ensures optimal tissue presentation and reduces the risk of tissue loss, supporting higher diagnostic confidence.
“We are thrilled to be the exclusive supplier of these consumables,” said Jeff Pemberton, VP of Marketing and Commercial Strategy. “Together, Mopec and Lumea are equipping labs with the tools they need to ensure consistency, reliability, and patient-focused outcomes.”
This expanded partnership exemplifies Mopec’s mission to empower pathology professionals with the industry’s leading platform of products and solutions. By combining state-of-the-art equipment with consumables designed to optimize pre-analytical processes, Mopec and Lumea are shaping the future of diagnostic accuracy and efficiency.
About Mopec Group
Mopec Group, headquartered in Madison Heights, Michigan, is a vertically integrated, branded supplier and manufacturer of high-quality anatomic and forensic pathology equipment, technology, consumable products, and services. Founded in 1992, Mopec Group differentiates itself through its innovation, engineering excellence, and outcome-focused mindset. Mopec Group is elevating pathology with complete solutions for labs in hospitals, universities, morgues, and beyond. For more information, visit www.mopecgroup.com and www.mopec.com.
About Lumea
Lumea is powering efficient, affordable, and accessible digital pathology through simplified, workflow-driven innovation with both tissue-handling technology and a best-in-class viewer with AI-driven workflows. As the U.S. leader in primary clinical digital pathology, processing the highest volume of digital cases nationwide. With over a decade of expertise, Lumea has set the standard for efficiency, quality, and premium cancer diagnostics. With a global presence spanning five continents, Lumea supports over half of the U.S. urology market and top dermatology and gastroenterology groups, optimizing tissue integrity, boosting detection rates, and delivering measurable ROI. By placing patients at the core, Lumea is transforming pathology for a more precise and efficient future. Learn more at www.lumeadigital.com.
Media Contact:
Jeff Pemberton
Vice President of Marketing & Commercial Strategy
[email protected]
o. 248.284.0871 | c. 810.300.2157
Bianca Collings
Lumea VP, Head of Marketing
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/mopec-expands-partnership-with-lumea-to-deliver-seamless-digital-pathology-integration-and-consumables-access-302568485.html
SOURCE Mopec
